Is proteomics of value in cardiovascular risk assessment?

TY - JOUR

T1 - Is proteomics of value in cardiovascular risk assessment?

AU - Arnold, Natalie

AU - Koenig, Wolfgang

PY - 2019/12

Y1 - 2019/12

N2 - PURPOSE OF REVIEW: To briefly summarize recently published evidence in the field of cardiovascular proteomics, focusing on its ability to improve cardiovascular risk stratification and critically discussing still open and burning issues and future perspectives of proteomics research.RECENT FINDINGS: Several epidemiological studies have demonstrated an improvement in cardiovascular risk prediction beyond traditional risk factors by adding novel biomarkers, identified by both discovery and targeted proteomics. However, only a moderate improvement in risk discrimination over clinical variables was observed. Moreover, despite different outcomes there was also a strong overlap of identified candidates, with several of them being already well established cardiovascular risk markers such as growth differentiation factor 15, natriuretic peptides, C-reactive protein, interleukins, and metalloproteases.SUMMARY: Although proteomics plays a crucial role in biomarker discovery, the modest discriminative ability of this technique raises the possibility that there are still hidden mechanisms in protein regulatory networks, which urgently need to be evaluated to improve a cardiovascular risk assessment to a clinically significant extent.

AB - PURPOSE OF REVIEW: To briefly summarize recently published evidence in the field of cardiovascular proteomics, focusing on its ability to improve cardiovascular risk stratification and critically discussing still open and burning issues and future perspectives of proteomics research.RECENT FINDINGS: Several epidemiological studies have demonstrated an improvement in cardiovascular risk prediction beyond traditional risk factors by adding novel biomarkers, identified by both discovery and targeted proteomics. However, only a moderate improvement in risk discrimination over clinical variables was observed. Moreover, despite different outcomes there was also a strong overlap of identified candidates, with several of them being already well established cardiovascular risk markers such as growth differentiation factor 15, natriuretic peptides, C-reactive protein, interleukins, and metalloproteases.SUMMARY: Although proteomics plays a crucial role in biomarker discovery, the modest discriminative ability of this technique raises the possibility that there are still hidden mechanisms in protein regulatory networks, which urgently need to be evaluated to improve a cardiovascular risk assessment to a clinically significant extent.

KW - Animals

KW - Biomarkers/metabolism

KW - C-Reactive Protein/metabolism

KW - Cardiovascular Diseases/metabolism

KW - Growth Differentiation Factor 15/metabolism

KW - Humans

KW - Interleukins/metabolism

KW - Metalloproteases/metabolism

KW - Natriuretic Peptides/metabolism

KW - Proteomics

KW - Risk Assessment

KW - Risk Factors

U2 - 10.1097/MOL.0000000000000639

DO - 10.1097/MOL.0000000000000639

M3 - SCORING: Review article

C2 - 31577609

VL - 30

SP - 452

EP - 461

JO - CURR OPIN LIPIDOL

JF - CURR OPIN LIPIDOL

SN - 0957-9672

IS - 6

ER -